Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

EWTX

Edgewise Therapeutics Inc

Dec 13 • 04:00PM ET

27.62

Dollar change -0.53
Percentage change -1.88	%

Healthcare • Biotechnology • USA • NASD

Peers: ALNY SRPT CRSP RARE BMRN PTCT QURE SGMO VYGR PRQR

| Held by: VTI IWM VXF IWO VTWO IBB SCHA XPH DFAC DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.49	Insider Own	34.09%	Shs Outstand	94.41M	Perf Week	-15.25%
Market Cap	2.57B	Forward P/E	-	EPS next Y	-1.83	Insider Trans	-1.00%	Shs Float	62.41M	Perf Month	-16.96%
Income	-124.29M	PEG	-	EPS next Q	-0.42	Inst Own	74.06%	Short Float	9.20%	Perf Quarter	63.82%
Sales	0.00M	P/S	-	EPS this Y	5.38%	Inst Trans	-0.38%	Short Ratio	5.13	Perf Half Y	57.74%
Book/sh	5.18	P/B	5.33	EPS next Y	-22.32%	ROA	-30.22%	Short Interest	5.74M	Perf Year	290.66%
Cash/sh	5.30	P/C	5.21	EPS next 5Y	-	ROE	-31.90%	52W Range	6.68 - 38.12	Perf YTD	152.47%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-68.02%	ROI	-25.25%	52W High	-27.54%	Beta	0.14
Dividend TTM	-	Quick Ratio	26.35	Sales past 5Y	0.00%	Gross Margin	-	52W Low	313.47%	ATR (14)	1.82
Dividend Ex-Date	-	Current Ratio	26.35	EPS Y/Y TTM	-5.64%	Oper. Margin	-	RSI (14)	31.86	Volatility	7.50% 5.53%
Employees	88	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	45.86
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	10.22%	Payout	-	Rel Volume	0.44	Prev Close	28.15
Sales Surprise	-	EPS Surprise	3.20%	Sales Q/Q	-	Earnings	Nov 07 BMO	Avg Volume	1.12M	Price	27.62
SMA20	-11.49%	SMA50	-15.29%	SMA200	24.90%	Trades		Volume	493,856	Change	-1.88%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-22-24	Initiated	Evercore ISI	Outperform	$45
Mar-07-24	Initiated	Piper Sandler	Overweight	$48
May-01-23	Initiated	Truist	Buy
Aug-25-22	Downgrade	Goldman	Neutral → Sell	$5
Apr-13-22	Initiated	RBC Capital Mkts	Outperform	$31
Jan-28-22	Initiated	Goldman	Neutral	$11

Dec-05-24 02:32PM	Edgewise Provides Statement Regarding Company's Relationship with Dr. Han Phan at Rare Disease Research (Business Wire)
Nov-26-24 06:00AM	Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 (Business Wire)
Nov-07-24 08:00AM	Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
Oct-07-24 05:37PM	Edgewise Therapeutics, Inc. (EWTX): A Hot Stock to Buy Now (Insider Monkey)
Oct-01-24 08:00AM	Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society (Business Wire)
07:28AM	Loading…
Sep-20-24 07:28AM	Novo sinks on obesity drug results; Sanofi reveals anticipated MS data (BioPharma Dive)
04:52AM	Edgewises EDG-7500 shows benefit in two obstructive HCM trials (Clinical Trials Arena)
Sep-19-24 04:08PM	How Edgewise, Up 55%, Is Hoping To Edge Out Bristol, Cytokinetics In Heart Disease (Investor's Business Daily) +54.69%
12:55PM	Why Edgewise Therapeutics Stock Is Up 50% on Thursday (Motley Fool)
09:22AM	Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip (Investor's Business Daily)
07:00AM	Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) (Business Wire)
Sep-17-24 04:01PM	Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time (Business Wire) +7.21% +5.50%
Aug-08-24 08:00AM	Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
Jul-30-24 12:25PM	7 Small-Cap Stocks to Buy for Large-Scale Gains (InvestorPlace) -5.49%
Jul-21-24 09:00AM	Dont Be Scared of Heights: J.P. Morgan Suggests 2 Stocks to Buy (TipRanks)
12:00PM	Loading…
Jul-17-24 12:00PM	Here's Why Edgewise Therapeutics, Inc. (EWTX) is a Great Momentum Stock to Buy (Zacks)
Jul-16-24 04:02PM	Three Surprising Names That Could Be On Biogen's Buyout Shortlist (Investor's Business Daily)
11:55AM	Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense (Investor's Business Daily)
May-10-24 01:38PM	Edgewise Therapeutics Inc (EWTX) Reports First Quarter 2024 Financial Results (GuruFocus.com) -8.35%
08:00AM	Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024 (Business Wire)
05:32AM	Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating (MT Newswires)
May-09-24 01:53PM	EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
May-07-24 08:00AM	Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors (Business Wire)
05:02AM	Edgewise Therapeutics doses first subject in HCM drug trial (Clinical Trials Arena)
May-06-24 09:01AM	Edgewise Therapeutics Says First Patient Dosed in Phase 2 Hypertrophic Cardiomyopathy Trial (MT Newswires)
08:00AM	Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM) (Business Wire)
Apr-23-24 09:34AM	Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU (MT Newswires)
08:00AM	Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies (Business Wire)
Apr-15-24 04:05PM	Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker) (Business Wire)
08:00AM	Loading…
Mar-28-24 08:00AM	Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session (Business Wire)
Mar-27-24 08:00AM	Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024 (Business Wire)
Mar-05-24 08:00AM	Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024 (Business Wire)
Feb-28-24 08:00AM	Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference (Business Wire)
Feb-26-24 09:55AM	Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know (Zacks)
Feb-22-24 08:00AM	Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (Business Wire)
Feb-21-24 09:21AM	13 Best Booming Stocks to Buy Right Now (Insider Monkey)
Feb-13-24 08:00AM	Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne) (Business Wire)
Feb-11-24 02:55PM	Insider Favorites: 7 Stocks with Bullish Buying Signals (InvestorPlace)
Feb-09-24 09:55AM	Wall Street Analysts See a 33.27% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High? (Zacks)
Jan-25-24 10:04PM	Edgewise Therapeutics Inc CFO R Carruthers Sells 90,000 Shares (GuruFocus.com) +5.02%
Jan-24-24 09:55AM	Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 70.76%: Read This Before Placing a Bet (Zacks)
Jan-22-24 02:06PM	Edgewise (EWTX) Rallies 35% on Issue of New Common Stock (Zacks) +19.25%
Jan-19-24 08:37AM	Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock (Business Wire) +34.57%
Jan-16-24 09:00AM	3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street (Motley Fool) -6.20%
Jan-09-24 08:39AM	Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-29-23 11:02PM	Edgewise Therapeutics Inc Director Jonathan Fox Acquires 10,857 Shares (GuruFocus.com)
Dec-19-23 08:00AM	Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 (Business Wire) +16.10%
Dec-18-23 08:00AM	Edgewise Therapeutics Launches First of Its Kind Educational Website Dedicated to the Becker Muscular Dystrophy Community (Business Wire) +8.23%
Nov-30-23 08:00AM	Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA (Business Wire)
Nov-28-23 07:29AM	Speculators Watch List: 7 Stocks Ripe for a Short-Squeeze Windfall (InvestorPlace)
Nov-09-23 09:41AM	Edgewise Therapeutics Inc (EWTX) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com) -7.29%
08:00AM	Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights (Business Wire)
Nov-08-23 08:00AM	Edgewise Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
Nov-01-23 08:00AM	Edgewise to Present Data on EDG-7500 at the American Heart Associations Scientific Sessions 2023 (Business Wire)
Oct-26-23 08:00AM	Edgewise Therapeutics Announces Expansion of their EDG-5506 Clinical Program in Duchenne Muscular Dystrophy (Duchenne) (Business Wire) -6.69%
Oct-10-23 09:55AM	Wall Street Analysts See a 310.1% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High? (Zacks) +6.84%
Sep-27-23 08:00AM	Edgewise Therapeutics to Present on EDG-5506 for Becker Muscular Dystrophy at the 28th International Annual Congress of the World Muscle Society (Business Wire)
Sep-26-23 08:00AM	Edgewise Therapeutics Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker) (Business Wire)
Sep-14-23 08:00AM	Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction (Business Wire) +5.65%
Sep-05-23 09:55AM	Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 327.91%: Read This Before Placing a Bet (Zacks)
Aug-31-23 10:12PM	11 Cheap Small-Cap Stocks to Buy Before the Next Breakout (Insider Monkey)
Aug-16-23 09:55AM	Wall Street Analysts Believe Edgewise Therapeutics, Inc. (EWTX) Could Rally 224.25%: Here's is How to Trade (Zacks)
Aug-10-23 08:00AM	Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights (Business Wire)
Jul-17-23 12:51PM	We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely (Simply Wall St.)
Jun-27-23 09:43AM	Edgewise Therapeutics Touts Positive Data From Investigational Drug In Form Of Muscular Dystrophy (Benzinga) +9.48%
Jun-26-23 04:01PM	Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD) (Business Wire) -9.74%
Jun-06-23 08:00AM	Edgewise Therapeutics to Present at the Goldman Sachs Global Healthcare Conference (Business Wire) +6.71%
May-11-23 08:00AM	Edgewise Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights (Business Wire)
May-02-23 08:00AM	Edgewise Therapeutics to Present at Upcoming Investor Conferences (Business Wire) -8.47%
Mar-30-23 04:01PM	Edgewise Therapeutics Announces Journal of Clinical Investigation Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models of Duchenne Muscular Dystrophy (DMD) (Business Wire)
Mar-21-23 08:00AM	Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023 (Business Wire)
Mar-14-23 08:00AM	Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific Conference (Business Wire)
Mar-06-23 08:00AM	Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors (Business Wire) -6.68%
Mar-01-23 08:00AM	Edgewise Therapeutics to Present at the Cowen 43rd Annual Health Care Conference on March 8, 2023 (Business Wire)
Feb-28-23 08:00AM	Edgewise Therapeutics Announces Upcoming Presentation at the American College of Cardiology's 72nd Annual Scientific Session Together with World Congress of Cardiology (Business Wire)
Feb-23-23 08:00AM	Edgewise Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights (Business Wire)
Feb-07-23 09:39AM	Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
08:00AM	Edgewise Therapeutics to Present at the SVB Securities Global Biopharma Conference on February 14, 2023 (Business Wire)
Jan-04-23 08:30AM	Edgewise Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 (Business Wire) +6.94%
Dec-21-22 09:00AM	Edgewise Therapeutics to Showcase Novel Cardiac Program at Virtual Investor Event on Tuesday, January 3, 2023 (Business Wire) +5.77%
Dec-20-22 09:00AM	Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer (Business Wire)
Nov-14-22 09:55AM	Wall Street Analysts Believe Edgewise Therapeutics, Inc. (EWTX) Could Rally 133%: Here's is How to Trade (Zacks)
Nov-09-22 08:00AM	Edgewise Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
Nov-03-22 08:00AM	Edgewise Therapeutics Reports Third Quarter 2022 Financial Results (Business Wire) +6.81%
Oct-27-22 04:05PM	Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD) (Business Wire) -5.75%
Oct-25-22 12:00PM	Edgewise Therapeutics, Inc. (EWTX) Upgraded to Buy: Here's What You Should Know (Zacks) +6.37%
09:55AM	Wall Street Analysts Believe Edgewise Therapeutics, Inc. (EWTX) Could Rally 157%: Here's is How to Trade (Zacks)
Oct-13-22 04:30PM	Edgewise Therapeutics Announces Positive 6-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD) (Business Wire)
Oct-06-22 08:00AM	Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 27th International Hybrid Annual Congress of the World Muscle Society (Business Wire)
Sep-23-22 06:35PM	Purple Innovation and Edgewise Therapeutics Stock See Action From Activist Investors (Barrons.com)
Sep-16-22 04:05PM	Edgewise Therapeutics Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire) -6.89%
Sep-13-22 09:17PM	Edgewise Therapeutics Announces Pricing of Upsized Public Offering of Common Stock (Business Wire) -24.01%
05:04PM	Edgewise (EWTX) Up 9.37% on Positive Data From BMD Study (Zacks)
08:49AM	Edgewise Therapeutics Announces Proposed Offering of Common Stock (Business Wire)
Sep-11-22 05:00PM	Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD) (Business Wire)
Sep-07-22 08:00AM	Edgewise Therapeutics Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD) (Business Wire) +8.29%
Aug-31-22 08:30AM	We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-04-22 08:00AM	Edgewise Therapeutics Reports Second Quarter 2022 Financial Results (Business Wire) +10.33%
Aug-03-22 08:00AM	Edgewise Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on August 9 (Business Wire)

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Carruthers R Michael	Chief Financial Officer	Oct 11 '24	Option Exercise	0.71	70,000	49,700	76,904	Oct 16 04:23 PM
Russell Alan J	Chief Scientific Officer	Sep 20 '24	Option Exercise	0.18	75,000	13,500	87,719	Sep 24 08:25 PM
Russell Alan J	Chief Scientific Officer	Sep 20 '24	Sale	28.27	75,000	2,120,101	12,719	Sep 24 08:25 PM
MOORE JOHN R	General Counsel	Sep 20 '24	Option Exercise	0.71	50,000	35,500	53,252	Sep 24 08:25 PM
MOORE JOHN R	General Counsel	Sep 23 '24	Option Exercise	0.71	20,922	14,855	24,174	Sep 24 08:25 PM
MOORE JOHN R	General Counsel	Sep 20 '24	Sale	28.37	50,000	1,418,510	3,252	Sep 24 08:25 PM
MOORE JOHN R	General Counsel	Sep 23 '24	Sale	27.63	20,922	578,064	3,252	Sep 24 08:25 PM
Donovan Joanne M.	CMO	Sep 20 '24	Sale	28.29	7,162	202,603	14,538	Sep 24 08:24 PM
Derakhshan Behrad	Chief Business Officer	Sep 20 '24	Option Exercise	1.93	42,068	81,191	57,189	Sep 24 08:24 PM
Derakhshan Behrad	Chief Business Officer	Sep 20 '24	Sale	29.03	42,068	1,221,133	15,121	Sep 24 08:24 PM
Carruthers R Michael	Chief Financial Officer	Sep 20 '24	Option Exercise	1.93	96,068	185,411	81,996	Sep 24 08:22 PM
Carruthers R Michael	Chief Financial Officer	Sep 20 '24	Sale	28.57	125,092	3,573,980	6,904	Sep 24 08:22 PM
JOHN R MOORE	Officer	Sep 23 '24	Proposed Sale	27.63	20,922	578,064		Sep 23 04:13 PM
JOANNE DONOVAN	Officer	Sep 20 '24	Proposed Sale	28.29	7,162	202,603		Sep 20 05:37 PM
Behrad Derakhshan	Officer	Sep 20 '24	Proposed Sale	29.50	50,000	1,475,000		Sep 20 04:46 PM
ALAN J RUSSELL	Officer	Sep 20 '24	Proposed Sale	28.27	75,000	2,120,100		Sep 20 04:29 PM
ROBERT MICHAEL CARRUTHERS	Officer	Sep 20 '24	Proposed Sale	28.57	125,092	3,573,980		Sep 20 04:11 PM
JOHN R MOORE	Officer	Sep 20 '24	Proposed Sale	28.37	50,000	1,418,510		Sep 20 04:08 PM
MOORE JOHN R	General Counsel	May 01 '24	Option Exercise	0.00	5,208	0	5,208	May 03 06:31 PM
MOORE JOHN R	General Counsel	May 02 '24	Sale	18.91	1,956	36,988	3,252	May 03 06:31 PM
Carruthers R Michael	Chief Financial Officer	May 01 '24	Option Exercise	0.00	5,208	0	37,387	May 03 06:30 PM
Carruthers R Michael	Chief Financial Officer	May 02 '24	Sale	18.91	2,157	40,789	35,230	May 03 06:30 PM
Derakhshan Behrad	Chief Business Officer	May 01 '24	Option Exercise	0.00	5,208	0	15,140	May 03 06:29 PM
Derakhshan Behrad	Chief Business Officer	May 02 '24	Sale	18.91	1,718	32,487	13,422	May 03 06:29 PM
Russell Alan J	Chief Scientific Officer	May 01 '24	Option Exercise	0.00	5,208	0	8,814	May 03 06:28 PM
Russell Alan J	Chief Scientific Officer	May 02 '24	Sale	18.91	1,576	29,802	7,238	May 03 06:28 PM
Donovan Joanne M.	CMO	May 01 '24	Option Exercise	0.00	10,417	0	23,579	May 03 06:27 PM
Donovan Joanne M.	CMO	May 02 '24	Sale	18.91	3,682	69,627	19,897	May 03 06:27 PM
KOCH KEVIN	President and CEO	May 01 '24	Option Exercise	0.00	10,417	0	17,630	May 03 06:26 PM
KOCH KEVIN	President and CEO	May 02 '24	Sale	18.91	3,152	59,604	14,478	May 03 06:26 PM
MOORE JOHN R	General Counsel	Feb 07 '24	Option Exercise	1.93	17,993	34,726	17,993	Feb 09 05:43 PM
MOORE JOHN R	General Counsel	Feb 09 '24	Option Exercise	1.93	8,029	15,496	8,029	Feb 09 05:43 PM
MOORE JOHN R	General Counsel	Feb 08 '24	Option Exercise	1.93	3,813	7,359	3,813	Feb 09 05:43 PM
MOORE JOHN R	General Counsel	Feb 07 '24	Sale	20.00	17,993	359,864	0	Feb 09 05:43 PM
MOORE JOHN R	General Counsel	Feb 09 '24	Sale	20.01	8,029	160,657	0	Feb 09 05:43 PM
MOORE JOHN R	General Counsel	Feb 08 '24	Sale	20.01	3,813	76,285	0	Feb 09 05:43 PM
Derakhshan Behrad	Chief Business Officer	Feb 09 '24	Option Exercise	1.93	4,800	9,264	11,820	Feb 09 05:42 PM
Derakhshan Behrad	Chief Business Officer	Feb 08 '24	Option Exercise	1.93	4,600	8,878	11,620	Feb 09 05:42 PM
Derakhshan Behrad	Chief Business Officer	Feb 07 '24	Option Exercise	1.93	600	1,158	7,620	Feb 09 05:42 PM
Derakhshan Behrad	Chief Business Officer	Feb 09 '24	Sale	20.04	4,800	96,209	7,020	Feb 09 05:42 PM
Derakhshan Behrad	Chief Business Officer	Feb 08 '24	Sale	20.01	4,600	92,049	7,020	Feb 09 05:42 PM
Derakhshan Behrad	Chief Business Officer	Feb 07 '24	Sale	20.00	600	12,000	7,020	Feb 09 05:42 PM
Carruthers R Michael	Chief Financial Officer	Jan 23 '24	Option Exercise	1.93	90,000	173,700	119,024	Jan 25 04:46 PM
Carruthers R Michael	Chief Financial Officer	Jan 23 '24	Sale	15.78	90,000	1,419,759	29,024	Jan 25 04:46 PM
Thompson Peter A.	Director	Jan 23 '24	Buy	11.00	454,545	4,999,995	14,436,497	Jan 25 04:32 PM
ORBIMED ADVISORS LLC	Director	Jan 23 '24	Buy	11.00	454,545	4,999,995	14,436,497	Jan 25 04:28 PM
Fox Jonathan C	Director	Dec 26 '23	Buy	9.30	10,857	100,958	10,857	Dec 28 04:39 PM
MOORE JOHN R	General Counsel	Dec 27 '23	Sale	10.50	8,497	89,218	0	Dec 28 04:39 PM
Russell Alan J	Chief Scientific Officer	Dec 26 '23	Sale	9.33	172,585	1,610,097	3,606	Dec 28 04:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EWTX

Edgewise Therapeutics Inc

Upgrade your FINVIZ experience